Drugs / GNR-051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04544748 | Jul 2020 → Nov 2022 | melanoma, non-small cell lung carcinoma, renal cell carcinoma | AO GENERIUM | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04544748 ↗ |
| Action | Inhibit | “GNR-051 is able to block the signaling molecule PD-1” NCT04544748 ↗ |
| Modality | Monoclonal antibody | “GNR-051 is a monoclonal antibody” NCT04544748 ↗ |